IRIS - Res&Arch Institutional Research Information System - Research & Archive

SALVADORI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.112
AS - Asia 1.324
EU - Europa 1.284
SA - Sud America 246
Continente sconosciuto - Info sul continente non disponibili 136
AF - Africa 48
OC - Oceania 9
Totale 5.159
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.026
SG - Singapore 562
IT - Italia 537
BR - Brasile 199
CN - Cina 170
HK - Hong Kong 161
IE - Irlanda 152
RU - Federazione Russa 107
KR - Corea 94
DE - Germania 84
VN - Vietnam 76
FR - Francia 69
NL - Olanda 52
GB - Regno Unito 51
BD - Bangladesh 46
IN - India 44
CA - Canada 43
SE - Svezia 39
FI - Finlandia 37
AT - Austria 30
TR - Turchia 30
RO - Romania 24
JP - Giappone 21
IQ - Iraq 20
PH - Filippine 19
PL - Polonia 17
CO - Colombia 16
ES - Italia 16
ZA - Sudafrica 16
BE - Belgio 13
UA - Ucraina 13
AR - Argentina 11
CH - Svizzera 10
MX - Messico 10
PK - Pakistan 10
AU - Australia 8
SA - Arabia Saudita 8
EC - Ecuador 7
IR - Iran 7
CR - Costa Rica 6
EG - Egitto 6
ID - Indonesia 6
LT - Lituania 6
MA - Marocco 6
TN - Tunisia 6
UZ - Uzbekistan 6
CW - ???statistics.table.value.countryCode.CW??? 5
IL - Israele 5
JM - Giamaica 5
MD - Moldavia 5
MY - Malesia 5
TW - Taiwan 5
CL - Cile 4
CZ - Repubblica Ceca 4
GT - Guatemala 4
JO - Giordania 4
KH - Cambogia 4
LB - Libano 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
OM - Oman 3
PA - Panama 3
PR - Porto Rico 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
GP - Guadalupe 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PY - Paraguay 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AM - Armenia 1
CV - Capo Verde 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
IS - Islanda 1
ML - Mali 1
MQ - Martinica 1
MR - Mauritania 1
MW - Malawi 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 5.026
Salva come PNG Salva come JPEG
Città #
Singapore 449
San Jose 214
Ashburn 196
Chandler 191
Hong Kong 149
Dublin 147
Perugia 136
Santa Clara 80
Boardman 58
San Mateo 56
Los Angeles 50
Council Bluffs 49
The Dalles 47
Beijing 44
Moscow 42
Lauterbourg 38
New York 38
Altamura 34
Ann Arbor 32
Redmond 31
Turin 30
Dearborn 28
Medford 28
Munich 28
Princeton 28
Seoul 27
Vienna 26
São Paulo 24
Ho Chi Minh City 23
Wilmington 22
Andover 20
Bucharest 20
Bologna 19
Dallas 19
Lawrence 18
Milan 18
Seongnam-si 18
Piscataway 16
Rome 15
Denver 14
Orem 14
Tokyo 14
Brussels 13
Montreal 13
Atlanta 12
Brooklyn 12
Falkenstein 12
Hanoi 12
Warsaw 12
Amsterdam 11
Boston 11
Falls Church 11
Phoenix 11
Toronto 11
Johannesburg 10
London 10
Nuremberg 10
Turku 10
Cebu City 9
Istanbul 9
North Bergen 9
Parma 9
Baghdad 8
Frankfurt am Main 8
Groningen 8
Helsinki 8
Brasília 7
Chennai 7
Da Nang 7
Florence 7
Houston 7
Mumbai 7
Redwood City 7
San Francisco 7
Seodaemun-gu 7
Collazzone 6
Des Moines 6
Dhaka 6
Glasgow 6
Incheon 6
Norwalk 6
Saint Petersburg 6
Buffalo 5
Cairo 5
Charlotte 5
Columbus 5
Dong Ket 5
Hefei 5
Naples 5
New Delhi 5
Stockholm 5
Willemstad 5
Woodbridge 5
Ankara 4
City of London 4
Jakarta 4
Jinju 4
Karaj 4
Konya 4
Lahore 4
Totale 2.987
Salva come PNG Salva come JPEG
Nome #
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 293
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 205
Histological muscle characterization in hypertrophied Marchigiana cattle breed 202
Intraperitoneal injection of microencapsulated Sertoli cells restores muscle morphology and performance in dystrophic mice 184
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 165
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 160
RAGE in the pathophysiology of skeletal muscle. 158
Equisetum arvense standardized extract hinders age-related sarcopenia 153
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 149
Generation of an mdx/Ager–/– double mutant mouse. Preliminary data on skeletal muscle architecture. 148
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 148
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 145
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 145
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 144
Natural products to counteract muscle atrophy 143
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 142
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 140
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 139
Effects of intraperitoneal injection of microencapsulated Sertoli cells on chronic and presymptomatic dystrophic mice 138
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 133
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 124
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 121
Mdx/Ager–/– mice show reduced muscle necrosis and inflammation compared with mdx mice 119
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 118
Beneficial effects of horsetail (Equisetum arvense) in in vitro models of sarcopenia and osteoporosis 117
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 115
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 115
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 112
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 111
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 110
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 107
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 107
The receptor RAGE: a potential molecular target in cancer cachexia 101
Sertoli cells induce utrophin expression in human DMD myotubes with different mutations and exert promyogenic and antifibrotic effects 99
Sertoli cells improve myogenic differentiation, reduce fibrogenic markers, and induce utrophin expression in human dmd myoblasts 84
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer 83
The novel DMD experimental model, mdx/Ager–/– mouse reveals a role of RAGE in inflammatory processes in dystrophic muscles. 83
Sertoli cells have promyogenic and antifibrotic effects, and induce utrophin expression in human DMD myotubes with different mutations in a heregulin β1/ErbB2/ERK1/2-dependent manner 60
Diet-Derived Advanced Glycation End-Products (AGEs) Induce Muscle Wasting In Vitro, and a Standardized Vaccinium macrocarpon Extract Restrains AGE Formation and AGE-Dependent C2C12 Myotube Atrophy 39
Totale 5.159
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022221 0 0 0 0 6 8 8 75 10 32 43 39
2022/2023548 30 104 3 49 44 61 1 25 198 2 22 9
2023/2024286 15 23 5 23 8 21 80 4 4 14 22 67
2024/20251.143 43 83 134 70 112 55 113 118 146 68 143 58
2025/20261.847 102 88 73 216 229 158 309 115 175 151 175 56
2026/2027616 158 58 105 246 49 0 0 0 0 0 0 0
Totale 5.159